Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 53 条
  • [31] Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction
    Mulhall, JP
    Montorsi, F
    [J]. EUROPEAN UROLOGY, 2006, 49 (01) : 30 - 37
  • [32] Geographic access to cancer care in the U.S
    Onega, Tracy
    Duell, Eric J.
    Shi, Xun
    Wang, Dongmei
    Demidenko, Eugene
    Goodman, David
    [J]. CANCER, 2008, 112 (04) : 909 - 918
  • [33] A Screening Tool to Enhance Clinical Trial Participation at a Community Center Involved in a Radiation Oncology Disparities Program
    Proctor, Julian W.
    Martz, Elaine
    Schenken, Larry L.
    Rainville, Rebecca
    Marlowe, Ursula
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (03) : 161 - 164
  • [34] The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research
    Rasco, Drew W.
    Xie, Yang
    Yan, Jingsheng
    Sayne, Jennifer R.
    Skinner, Celette Sugg
    Dowell, Jonathan E.
    Gerber, David E.
    [J]. ONCOLOGIST, 2009, 14 (05) : 468 - 475
  • [35] Ruckdeschel J C, 1996, J Cancer Educ, V11, P73
  • [36] Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patients
    Sabesan, Sabe
    Burgher, Bjourn
    Buettner, Petra
    Piliouras, Peter
    Otty, Zulfiquer
    Varma, Suresh
    Thaker, Darshit
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (01) : 27 - 33
  • [37] How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials
    Sateren, WB
    Trimble, EL
    Abrams, J
    Brawley, O
    Breen, N
    Ford, L
    McCabe, M
    Kaplan, R
    Smith, M
    Ungerleider, R
    Christian, MC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2109 - 2117
  • [38] Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the prostate-specific antigen working group
    Scher, HI
    Eisenberger, M
    D'Amico, AV
    Halabi, S
    Small, EJ
    Morris, M
    Kattan, MW
    Roach, M
    Kantoff, P
    Pienta, KJ
    Carducci, MA
    Agus, D
    Slovin, SF
    Heller, G
    Kelly, WK
    Lange, PH
    Petrylak, D
    Berg, W
    Higano, C
    Wilding, G
    Moul, JW
    Partin, AN
    Logothetis, C
    Soule, HR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) : 537 - 556
  • [39] Study design issues and early stage non-small cell lung cancer
    Schiller, JH
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5030S - 5032S
  • [40] Schutta K M, 2000, Oncol Nurs Forum, V27, P1435